Current Cancer Drug Targets
Title:Meet Our Editorial Board Member
Volume: 16 Issue: 9
Author(s): Ingunn Holen
Affiliation:
Export Options
About this article
Cite this article as:
Holen Ingunn, Meet Our Editorial Board Member, Current Cancer Drug Targets 2016; 16 (9) . https://dx.doi.org/10.2174/156800961609161017160614
DOI https://dx.doi.org/10.2174/156800961609161017160614 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
31
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stem Cells for Microenvironmental Modulation and Retinal Regeneration
Current Tissue Engineering (Discontinued) A Simple and Sensitive LC-MS/MS Method for the Simultaneous Determination of Cyclophosphamide and Doxorubicin Concentrations in Human Plasma
Current Pharmaceutical Analysis Molecular and Biological Functions of Melatonin in Endometrial Cancer
Current Drug Targets In vivo Real-Time Near-Infrared Fluorescent Mapping of Sentinel Lymph Nodes Using Methylene Blue Encapsulated in a Microemulsion Nanosystem
Current Nanoscience Radiolabelled Quinoline Derivaties for the PET Imaging of Peripheral Benzodiazepine Receptor
Current Medical Imaging An Integrated Drug Development Approach Applying Topological Descriptors
Current Computer-Aided Drug Design Meet Our Editorial Board Member
Mini-Reviews in Medicinal Chemistry The Expression of Dopamine Receptors Gene and their Potential Role in Targeting Breast Cancer Cells with Selective Agonist and Antagonist Drugs. Could it be the Novel Insight to Therapy?
Current Drug Discovery Technologies A Family of Pleiotropically Acting MicroRNAs in Cancer Progression, miR-200: Potential Cancer Therapeutic Targets
Current Pharmaceutical Design Development of COX-2 Selective Inhibitors - Therapeutic Perspectives
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents MicroRNAs as Biomarker for Breast Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Prodrugs for Targeted Tumor Therapies: Recent Developments in ADEPT, GDEPT and PMT
Current Pharmaceutical Design Possible Exploitation of Non-Neuronal and Non-Chemical Synaptic Signalling Pathways in Epilepsy Therapy
Current Signal Transduction Therapy Simultaneous Analysis of Vanillin and Coumarin in Mangrove Plants and Commercial Food Products Using UPLC-ESI-MS/MS
Current Analytical Chemistry Modulation of Hepatic MRP3/ABCC3 by Xenobiotics and Pathophysiological Conditions: Role in Drug Pharmacokinetics
Current Medicinal Chemistry Steroid Regulation of Drug-Metabolizing Cytochromes P450
Current Drug Metabolism Tumorspheres Derived from HCC Cells are Enriched with Cancer Stem Cell-like Cells and Present High Chemoresistance Dependent on the Akt Pathway
Anti-Cancer Agents in Medicinal Chemistry The Potential Anti-Tumorigenic and Anti-Metastatic Side of the Proprotein Convertases Inhibitors
Recent Patents on Anti-Cancer Drug Discovery Genetic Dissection of Complex Traits In Silico: Approaches, Problems and Solutions
Current Bioinformatics Breast Reconstruction – A Historical Perspective on Available Techniques for Patients Electing Bilateral Mastectomy
Current Cancer Therapy Reviews